Sugi Predict

Sugi Predict / Compounds / SCHEMBL4487979

SCHEMBL4487979

SCHEMBL4487979

COCCc1sc2ncnc(N)c2c1-c1ccc(NC(=O)Nc2ccccc2C)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 17/20 0.76
▸ TEK Q02763 16/20 0.76
▸ KIT P10721 15/20 0.76
▸ AURKA O14965 2/20 0.60
▸ PLK4 O00444 1/20 0.57
▸ PDPK1 O15530 1/20 0.57
▸ PRKD3 O94806 1/20 0.57
▸ MAP4K4 O95819 1/20 0.57
▸ CHEK2 O96017 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ CDK1 P06493 1/20 0.57
▸ MET P08581 1/20 0.57
▸ PIM1 P11309 1/20 0.57
▸ PHKG2 P15735 1/20 0.57
▸ MARK3 P27448 1/20 0.57
▸ AXL P30530 1/20 0.57
▸ AKT2 P31751 1/20 0.57
▸ MAPKAPK2 P49137 1/20 0.57
▸ GSK3B P49841 1/20 0.57
▸ BLK P51451 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465929 0.90 KDR (0.76) KDRTEKKITAURKAPLK4
SCHEMBL4490266 0.89 KDR (0.83) KDRTEKKITAURKAPLK4
SCHEMBL4477135 0.87 KDR (0.76) KDRTEKKITAURKAPLK4
SCHEMBL4489547 0.86 KDR (1.00) KDRTEKKIT
SCHEMBL4473058 0.85 KDR (0.71) KDRTEKKITAURKA
SCHEMBL4476734 0.84 KDR (1.00) KDRTEKKITAURKAPLK4
SCHEMBL4471343 0.84 KDR (0.83) KDRTEKKIT
SCHEMBL4476102 0.84 KDR (0.83) KDRTEKKIT
SCHEMBL4487356 0.83 KDR (0.81) KDRTEKKITAURKAPRKD3
SCHEMBL4470994 0.82 KDR (0.80) KDRTEKKITAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-09-25 — — US claimed
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885TEK 324/4885KIT 361/4885
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 462/4885TEK 340/4885KIT 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.